Compared with oral and injectable formulations, it is much more complicated in semisolid and suspension formulations for topical usage from the technical points of view. Due to the characteristics of multiple phases, irregular drug release kinetics and degradation thermodynamics, and generally without systemic absorption, the formulation development and characterization of topical semisolid drug products are facing challenges. Referring to the relevant technical guidelines issued by FDA, EMA and Center for Drug Evaluation of China as well as literature, this paper analyzes the key technical points on topical dermatologic drugs for Q3 equivalence study, including the critical quality attributes, in vitro release test(IVRT) and in vitro permeation test(IVPT), hoping to provide some references for in vitro consistency of generic drugs.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |